Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease

Arthur J. Kastl; Kimberly N Weaver; Xian Zhang; Jennifer A Strople; Jeremy Adler; Judith R Kelsen; Marla C Dubinsky; Athos Bousvaros; Runa Watkins; Colin Dai; Raymond K Cross; Peter D R. Higgins; Ryan Ungaro; Meenakshi Bewtra; Emanuelle A. Bellaguarda; Francis A. Farraye; Kelly Chun; Michael Zikry; Monique Bastidas; Margie E Boccieri; Ann Firestine; Millie D Long; Michael D Kappelman

doi:10.1002/jpn3.12142

Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease

Arthur J. Kastl^*, Kimberly N Weaver, Xian Zhang, Jennifer A Strople, Jeremy Adler, Judith R Kelsen, Marla C Dubinsky, Athos Bousvaros, Runa Watkins, Colin Dai, Raymond K Cross, Peter D R. Higgins, Ryan Ungaro, Meenakshi Bewtra, Emanuelle A. Bellaguarda, Francis A. Farraye, Kelly Chun, Michael Zikry, Monique Bastidas, Margie E BoccieriAnn Firestine, Millie D Long, Michael D Kappelman

^*Corresponding author for this work

Medicine, Gastroenterology Division

Research output: Contribution to journal › Article › peer-review

Abstract

Children with very early onset inflammatory bowel disease (VEO-IBD) may respond differently to coronavirus disease 2019 (COVID-19) immunization compared to healthy children or other patients with IBD. We recruited children with VEO-IBD <6 years of age and younger following receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Demographics, IBD characteristics, medication use, adverse events (AEs) and IBD exacerbations were collected. Blood draws (optional) were obtained for measurement of antireceptor binding domain (RBD) IgG antibodies following vaccination. Of 41 participants, none required emergency department visit or hospitalization due to AE, and only one experienced IBD exacerbation. Detectable antibody was present in 19/19 participants who provided blood sample; 6/7 participants (86%) had durable humoral response 12 months postvaccination. Children with VEO-IBD experience robust humoral immune response to COVID-19 immunization. Severe AEs were rare. These findings provide reassurance that children with VEO-IBD respond well and safely to SARS-CoV-2 vaccination.

Original language	English (US)
Pages (from-to)	871-877
Number of pages	7
Journal	Journal of pediatric gastroenterology and nutrition
Volume	78
Issue number	4
DOIs	https://doi.org/10.1002/jpn3.12142
State	Published - Apr 2024

Keywords

COVID-19
Moderna
Pfizer
antibody
vaccine

ASJC Scopus subject areas

Gastroenterology
Pediatrics, Perinatology, and Child Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/jpn3.12142

Cite this

Kastl, A. J., Weaver, KN., Zhang, X., Strople, JA., Adler, J., Kelsen, JR., Dubinsky, MC., Bousvaros, A., Watkins, R., Dai, C., Cross, RK., Higgins, PD. R., Ungaro, R., Bewtra, M., Bellaguarda, E. A., Farraye, F. A., Chun, K., Zikry, M., Bastidas, M., ... Kappelman, MD. (2024). Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease. Journal of pediatric gastroenterology and nutrition, 78(4), 871-877. https://doi.org/10.1002/jpn3.12142

@article{f1ccdd7d3b56495d8825de646f9c87a3,

title = "Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease",

abstract = "Children with very early onset inflammatory bowel disease (VEO-IBD) may respond differently to coronavirus disease 2019 (COVID-19) immunization compared to healthy children or other patients with IBD. We recruited children with VEO-IBD <6 years of age and younger following receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Demographics, IBD characteristics, medication use, adverse events (AEs) and IBD exacerbations were collected. Blood draws (optional) were obtained for measurement of antireceptor binding domain (RBD) IgG antibodies following vaccination. Of 41 participants, none required emergency department visit or hospitalization due to AE, and only one experienced IBD exacerbation. Detectable antibody was present in 19/19 participants who provided blood sample; 6/7 participants (86%) had durable humoral response 12 months postvaccination. Children with VEO-IBD experience robust humoral immune response to COVID-19 immunization. Severe AEs were rare. These findings provide reassurance that children with VEO-IBD respond well and safely to SARS-CoV-2 vaccination.",

keywords = "COVID-19, Moderna, Pfizer, antibody, vaccine",

author = "Kastl, {Arthur J.} and Kimberly N Weaver and Xian Zhang and Jennifer A Strople and Jeremy Adler and Judith R Kelsen and Marla C Dubinsky and Athos Bousvaros and Runa Watkins and Colin Dai and Raymond K Cross and Higgins, {Peter D R.} and Ryan Ungaro and Meenakshi Bewtra and Bellaguarda, {Emanuelle A.} and Farraye, {Francis A.} and Kelly Chun and Michael Zikry and Monique Bastidas and Margie E Boccieri and Ann Firestine and Millie D Long and Michael D Kappelman",

note = "Publisher Copyright: {\textcopyright} 2024 European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.",

year = "2024",

month = apr,

doi = "10.1002/jpn3.12142",

language = "English (US)",

volume = "78",

pages = "871--877",

journal = "Journal of pediatric gastroenterology and nutrition",

issn = "0277-2116",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

Kastl, AJ, Weaver, KN, Zhang, X, Strople, JA, Adler, J, Kelsen, JR, Dubinsky, MC, Bousvaros, A, Watkins, R, Dai, C, Cross, RK, Higgins, PDR, Ungaro, R, Bewtra, M, Bellaguarda, EA, Farraye, FA, Chun, K, Zikry, M, Bastidas, M, Boccieri, ME, Firestine, A, Long, MD & Kappelman, MD 2024, 'Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease', Journal of pediatric gastroenterology and nutrition, vol. 78, no. 4, pp. 871-877. https://doi.org/10.1002/jpn3.12142

TY - JOUR

T1 - Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease

AU - Kastl, Arthur J.

AU - Weaver, Kimberly N

AU - Zhang, Xian

AU - Strople, Jennifer A

AU - Adler, Jeremy

AU - Kelsen, Judith R

AU - Dubinsky, Marla C

AU - Bousvaros, Athos

AU - Watkins, Runa

AU - Dai, Colin

AU - Cross, Raymond K

AU - Higgins, Peter D R.

AU - Ungaro, Ryan

AU - Bewtra, Meenakshi

AU - Bellaguarda, Emanuelle A.

AU - Farraye, Francis A.

AU - Chun, Kelly

AU - Zikry, Michael

AU - Bastidas, Monique

AU - Boccieri, Margie E

AU - Firestine, Ann

AU - Long, Millie D

AU - Kappelman, Michael D

PY - 2024/4

Y1 - 2024/4

N2 - Children with very early onset inflammatory bowel disease (VEO-IBD) may respond differently to coronavirus disease 2019 (COVID-19) immunization compared to healthy children or other patients with IBD. We recruited children with VEO-IBD <6 years of age and younger following receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Demographics, IBD characteristics, medication use, adverse events (AEs) and IBD exacerbations were collected. Blood draws (optional) were obtained for measurement of antireceptor binding domain (RBD) IgG antibodies following vaccination. Of 41 participants, none required emergency department visit or hospitalization due to AE, and only one experienced IBD exacerbation. Detectable antibody was present in 19/19 participants who provided blood sample; 6/7 participants (86%) had durable humoral response 12 months postvaccination. Children with VEO-IBD experience robust humoral immune response to COVID-19 immunization. Severe AEs were rare. These findings provide reassurance that children with VEO-IBD respond well and safely to SARS-CoV-2 vaccination.

AB - Children with very early onset inflammatory bowel disease (VEO-IBD) may respond differently to coronavirus disease 2019 (COVID-19) immunization compared to healthy children or other patients with IBD. We recruited children with VEO-IBD <6 years of age and younger following receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Demographics, IBD characteristics, medication use, adverse events (AEs) and IBD exacerbations were collected. Blood draws (optional) were obtained for measurement of antireceptor binding domain (RBD) IgG antibodies following vaccination. Of 41 participants, none required emergency department visit or hospitalization due to AE, and only one experienced IBD exacerbation. Detectable antibody was present in 19/19 participants who provided blood sample; 6/7 participants (86%) had durable humoral response 12 months postvaccination. Children with VEO-IBD experience robust humoral immune response to COVID-19 immunization. Severe AEs were rare. These findings provide reassurance that children with VEO-IBD respond well and safely to SARS-CoV-2 vaccination.

KW - COVID-19

KW - Moderna

KW - Pfizer

KW - antibody

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85189907765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85189907765&partnerID=8YFLogxK

U2 - 10.1002/jpn3.12142

DO - 10.1002/jpn3.12142

M3 - Article

C2 - 38356293

AN - SCOPUS:85189907765

SN - 0277-2116

VL - 78

SP - 871

EP - 877

JO - Journal of pediatric gastroenterology and nutrition

JF - Journal of pediatric gastroenterology and nutrition

IS - 4

ER -

Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this